Latest Orexo News & Updates

See the latest news and media coverage for Orexo. We track all announcements, press releases, and industry mentions in real time, all in one place.

Orexo

Pharmaceutical company developing medicines using formulation technologies

orexo.se

Headquarters: Fyrislund, Sweden
Founded year: 1995
Company type: Public company
Number of employees: 83–200
Industry: Pharmaceuticals

Last updated October 29

Latest news about Orexo

In short: Orexo gained FDA acceptance for IZIPRY, posted Q3 loss and moved to settle DOJ probe

Company announcements

October 29 Orexo

Orexo receives FDA review for IZIPRY™ application

The regulatory authority has accepted the resubmitted application with a six-month evaluation period, target date March 29, 2027.

October 22 Orexo

Orexo presents interim report for Q3 2026

The company reported a loss of -117.9 mkr and reached a principle agreement with the DOJ. The Zyprexa application was resubmitted to the FDA and OX640 received IND approval.

October 6 Orexo

Orexo plans a 250 MSEK rights issue to finance development and legal settlements

Proceeds fund OX640 trials, Izipry regulatory processes, and DOJ settlement. Commitments cover 70% of the total amount needed.

July 16 Orexo

Orexo provides Q2 2026 business update and financing plans

The company advances OX640, Izipry, and OX390 trials, initiates financing with DNB Carnegie, and continues DOJ negotiations while restructuring.

Media coverage

October 21 RTTNews

Orexo AB Q3 Loss Climbs

Orexo AB (ORX.ST) revealed Loss for its third quarter of -SEK117.9 million The company's earnings came in at -SEK117.9 million, or -SEK3.36 per share. This...

October 13 EFN

Orexo shows promising results for semaglutid tablet

Specialist pharmaceutical company Orexo announces initial results from its first preclinical pharmacokinetic in vivo study of an oral semaglutid tablet. The study showed that a tablet based on Amorphox...

October 5 Dagens industri

Orexo plans to raise half a billion in new share issue

The pharmaceutical company Orexo, which has a market value of 500 million kronor, has decided to carry out a new share issue of approximately 250 million kronor...

September 28 The Pharma Letter

Orexo resubmits NDA for Izipry to the FDA

Sweden's Orexo today announced the resubmission of the New Drug Application (NDA) for Izipry (naloxone nasal powder) to the US Food and Drug Administration (FDA...

Never miss news about Orexo

Track Orexo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Orexo competitors & trending companies

Browse news for competitors to Orexo and other trending companies.